Vaxcyte Pre-Tax Income 2019-2024 | PCVX

  • Vaxcyte annual pre-tax income for 2024 was $-0.464B, a 15.33% increase from 2023.
  • Vaxcyte annual pre-tax income for 2023 was $-0.402B, a 80% increase from 2022.
  • Vaxcyte annual pre-tax income for 2022 was $-0.223B, a 123.31% increase from 2021.

Historical Chart (TTM)

Click on chart icon to view chart
Click on table icon to view table

Quarterly

Click on chart icon to view chart
Click on table icon to view table

Quarterly - YOY Change

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table

Annual % Change

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.9B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$134.2B
Vertex Pharmaceuticals (VRTX)$121.1B
Bristol Myers Squibb (BMY)$111.6B
CSL (CSLLY)$80.7B
GSK (GSK)$75.7B
Regeneron Pharmaceuticals (REGN)$75B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$23.2B
Biogen (BIIB)$20B
Illumina (ILMN)$16.3B
Insmed (INSM)$15B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.4B
Moderna (MRNA)$13.8B
Intra-Cellular Therapies (ITCI)$13.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Bio-Techne Corp (TECH)$10.4B
Sarepta Therapeutics (SRPT)$10.2B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.3B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.7B
Repligen (RGEN)$8.4B